4-HO-DBT

Psychedelic drug From Wikipedia, the free encyclopedia

4-HO-DBT, also known as 4-hydroxy-N,N-dibutyltryptamine, is a psychedelic drug of the tryptamine family related to psilocin (4-HO-DMT).[1] It is taken orally.[1]

Other names4-OH-DBT; 4-Hydroxy-N,N-dibutyltryptamine
ATC code
  • None
Quick facts Clinical data, Other names ...
4-HO-DBT
Clinical data
Other names4-OH-DBT; 4-Hydroxy-N,N-dibutyltryptamine
Routes of
administration
Oral[1]
Drug classSerotonergic psychedelic; Hallucinogen
ATC code
  • None
Identifiers
  • N-butyl-N-[2-(4-hydroxy-1H-indol-3-yl)ethyl]butan-1-amine
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC18H28N2O
Molar mass288.435 g·mol−1
3D model (JSmol)
Melting point74 to 75 °C (165 to 167 °F)
  • CCCCN(CCCC)CCc2c[nH]c1cccc(O)c12
  • InChI=1S/C18H28N2O/c1-3-5-11-20(12-6-4-2)13-10-15-14-19-16-8-7-9-17(21)18(15)16/h7-9,14,19,21H,3-6,10-13H2,1-2H3 checkY
  • Key:BDOJPNJIBDXWQQ-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)
Close

Use and effects

In his book TiHKAL (Tryptamines I Have Known and Loved), Alexander Shulgin reported that a 20 mg dose of 4-HO-DBT orally produced no effects.[1] However, this compound has subsequently been sold as a "research chemical" and anecdotal reports suggest that at higher doses 4-HO-DBT is indeed an active hallucinogen, although somewhat weaker than other similar tryptamine derivatives.[citation needed]

Interactions

Chemistry

Properties

4-HO-DBT is found either as its crystalline hydrochloride salt or as an oily or crystalline base.

Synthesis

The chemical synthesis of 4-HO-DBT has been described.[1]

Isomers

Several different isomers of 4-HO-DBT could be made, including 4-HO-DiBT, 4-HO-DsBT, and 4-HO-DtBT, but of these only the isobutyl isomer 4-HO-DiBT was synthesized by Alexander Shulgin (melting point 152 to 154 °C) and was also found to be inactive at a 20 mg dose.[1] The serotonin receptor interactions of these isomers have been studied.[2] 4-HO-DiBT showed 43-fold lower affinity and 4-HO-DsBT 6.5-fold lower affinity for the serotonin 5-HT2A receptor compared to psilocin (4-HO-DMT).[2]

History

4-HO-DBT was first described in the scientific literature by David Repke and colleagues in 1977.[3] It was subsequently described in further detail by Alexander Shulgin in his 1997 book TiHKAL (Tryptamines I have Known and Loved).[1]

See also

References

Related Articles

Wikiwand AI